Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Action: Physiological Effects

Effect of the Echinocandin Caspofungin on Expression of Candida albicans Secretory Aspartyl Proteinases and Phospholipase In Vitro

Jean-Sébastien Ripeau, Francine Aumont, Pierre Belhumeur, Luis Ostrosky-Zeichner, John H. Rex, Louis de Repentigny
Jean-Sébastien Ripeau
1Department of Microbiology and Immunology, Faculty of Medicine, University of Montreal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francine Aumont
1Department of Microbiology and Immunology, Faculty of Medicine, University of Montreal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Belhumeur
1Department of Microbiology and Immunology, Faculty of Medicine, University of Montreal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luis Ostrosky-Zeichner
2Division of Infectious Diseases, University of Texas Medical School, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John H. Rex
2Division of Infectious Diseases, University of Texas Medical School, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louis de Repentigny
1Department of Microbiology and Immunology, Faculty of Medicine, University of Montreal
3Sainte-Justine Hospital, Montreal, Quebec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: louis.de.repentigny@umontreal.ca
DOI: 10.1128/AAC.46.9.3096-3100.2002
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Although the echinocandin caspofungin primarily inhibits the synthesis of cell wall 1,3-β-d-glucan, its fungicidal activity could also potentially perturb the expression of virulence factors involved in the ability of Candida albicans to cause infection. Expression of the C. albicans secretory aspartyl proteinase (SAP) and phospholipase B (PLB) virulence genes was determined by reverse transcription-PCR after the addition of caspofungin to cells grown for 15 h in Sabouraud dextrose broth. In cells that remained viable, expression of SAP1 to SAP3, SAP7 to SAP9, and PLB1 was unaltered after exposure to fungicidal concentrations (4 to 16 μg/ml) of caspofungin over a period of 7 h. However, expression of SAP5 increased steadily beginning 1 h after exposure to caspofungin. These results indicate that caspofungin is rapidly fungicidal against C. albicans, before any suppression of SAP or PLB1 gene expression can occur.

The cyclic lipopeptide pneumocandins and echinocandins and the glycolipid papulacandins are members of a new class of antifungal agents which exert their activity by noncompetitive inhibition of fungal 1,3-β-d-glucan synthase (5, 17, 22, 30, 37). This enzyme is essential for the synthesis of cell wall glucan which provides structural integrity and osmotic stability for fungi but is not found in cells from higher eukaryotes including humans. Disruption of cell wall structure by inhibition of glucan synthesis results in osmotic instability and lysis of the fungal cell (12, 37). Caspofungin (MK-0991) is a water-soluble semisynthetic amine derivative of the natural product pneumocandin Bo (17, 26, 37), which in turn is a fermentation product derived from the fungus Glarea lozoyensis (9). Caspofungin was developed as a potential antifungal and anti-Pneumocystis agent (17, 26, 37). In vitro, caspofungin is fungicidal against Candida species, including azole-resistant species, and is fungistatic against Aspergillus species (6, 8, 15, 28, 33, 39, 45). However, it is inactive against Fusarium, Rhizopus, Trichosporon, and Cryptococcus neoformans (8, 15, 28, 39). In addition to prolonging survival in mouse models of disseminated candidiasis and aspergillosis (1, 2, 20, 21), caspofungin has recently shown promising clinical activity for the treatment of life-threatening infections caused by Candida and Aspergillus species (46; J. Maertens, I. Raad, C. A. Sable, A. Ngai, R. Berman, T. F. Patterson, D. Denning, and T. Walsh, Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1103, 2000; A. Villanueva, E. Gotuzzo, E. Arathoon, L. M. Noriega, N. Kartsonis, R. Lupinacci, J. Smietana, R. S. Berman, M. J. Dinubile, and C. A. Sable, Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother., abstr. J-675, 2001).

Because caspofungin is fungicidal, it could potentially affect a diversity of cellular processes which contribute to the ability of Candida albicans to cause infection. The primary mechanism of action of pneumocandins and echinocandins is inhibition of synthesis of cell wall 1,3-β-d-glucan, and these compounds do not inhibit other C. albicans membrane-bound enzymes, such as chitin synthase or serine palmitoyltransferase (29). However, echinocandin antimycotics inhibit the incorporation of glucan-associated enolase into the growing cell wall of C. albicans (3). In addition, although the synthesis of C. albicans RNA is only modestly inhibited at the MIC of the pneumocandin L-733,560, a close analogue of caspofungin, marked inhibition occurs at 250 times the MIC (29).

Fungal virulence factors are attracting attention as potential targets for drug development (18, 38). C. albicans secretory aspartyl proteinases (Saps), under the control of a multigene family (SAP1 to SAP9) expressing distinct isoenzymes which are regulated differentially at the mRNA level in vitro (24, 34) and in vivo (35, 41), are implicated in the breakdown of several host substrates (23). There is evidence that phospholipase B expressed by at least two genes (PLB1 and PLB2) (32, 44) also contributes to the pathogenesis of candidiasis by the degradation of host tissues (19, 25). The potential impact of antifungal therapies on expression of C. albicans virulence factors is exemplified by the enhanced production of Sap by azole-resistant C. albicans isolates from a patient infected with human immunodeficiency virus after growth in subinhibitory concentrations of fluconazole (49). In the present study, we sought to determine whether caspofungin could potentially exert added anticandidal activity by inhibiting the expression of C. albicans SAPs and PLB1, as a consequence of nonspecific effects on transcription.

Candida strains.

Sap- and phospholipase-producing (11, 13, 41) C. albicans LAM-1 (serotype A) was originally isolated from the blood of a patient with systemic candidiasis (31). The isolate was stored at −80°C in a solution containing 65% (vol/vol) glycerol, 10 mM Tris (pH 7.5), and 10 mM MgCl2. Prior to use, Candida was cultured at 37°C on Sabouraud dextrose agar (SDA) (Becton Dickinson and Company, Cockeysville, Md.).

Antifungal susceptibility testing.

The susceptibility of C. albicans strain LAM-1 to antifungal agents was determined by the broth microdilution version (16) of the M27-A method defined by the National Committee for Clinical Laboratory Standards (36). The method was performed in RPMI 1640 medium (Gibco BRL, Gaithersburg, Md.) buffered to pH 7.0 with 0.165 M morpholinepropanesulfonic acid (MOPS) buffer (MOPS-buffered RPMI; ICN Biochemicals, Cleveland, Ohio) with readings at 48 h, except for amphotericin B, which was tested in antibiotic medium 3 and read after 24 h (47). The MICs of the azoles and flucytosine were defined as the lowest concentrations giving prominent growth reduction. For the other drugs, the MIC was the lowest drug concentration giving an optically clear well. Candida parapsilosis ATCC 22019 and Candida krusei ATCC 6258 (40) were included as quality control isolates (7). After 48 h, 20 μl of each clear well was plated on SDA, and the minimum fungicidal concentration (MFC) was the lowest concentration giving no growth (>98% killing).

Time-kill curve procedures.

Caspofungin (MK-0991) was provided as a pure white powder by the Merck Research Laboratories (Rahway, N.J.) and stored at −80°C. A stock solution at a concentration of 400 μg/ml was prepared in sterile distilled water for each experiment.

Three to five colonies of C. albicans grown for 24 to 48 h on SDA were suspended in 5 ml of 0.01 M phosphate-buffered saline (pH 7.2), and the cells were counted using a hemacytometer. An appropriate volume of fungal suspension was then added to Erlenmeyer flasks containing 70 ml of either Sabouraud dextrose broth (SDB; Difco Laboratories, Detroit, Mich.) or MOPS-buffered RPMI to yield a starting inoculum of approximately 103 CFU/ml. Caspofungin was added to individual cultures with resulting concentrations ranging from 0.125 to 16 μg/ml, either at the start of culture or after 15 h of incubation with rotary agitation at 37°C. Culture medium without drug served as a growth control. At predetermined time points, duplicate 100-μl volumes were withdrawn from each culture and serially diluted (10-fold), and a 100-μl aliquot from each dilution was plated on SDA for determination of CFU. The results were expressed as the averages of the duplicate CFU determinations. When colony counts were anticipated to be less than 103 CFU/ml, duplicate 0.1-ml aliquots of the cultures were plated directly on SDA without dilution. A 1-ml aliquot of each culture was also removed at the same time points and centrifuged, and the pellet was immediately frozen at −80°C for analysis of C. albicans SAP and PLB1 gene expression.

RT-PCR.

Isolation of RNA from the pelleted cells and reverse transcription-PCR (RT-PCR) were performed as previously described (41). In order to assess gene expression by the portion of C. albicans which remained viable during the time-kill experiments, RT-PCR for each gene and time point was conducted using an amount of RNA originating from 1,400 CFU of C. albicans. For the detection of gene expression, individual digoxigenin-labeled probes were used to specifically detect each of the RT-PCR products by Southern blotting (41). Positive controls for expression of each of the individual SAP and PLB1 genes were included in the RT-PCR assay, using RNA from C. albicans LAM-1 grown in vitro under conditions known to induce their expression. The EFB1 gene was amplified as a positive mRNA control and to detect any contaminating genomic DNA by the presence of a 365-bp intron (41). A negative control for expression of each gene was obtained by omitting the RNA in the RT-PCR assay (41).

The MICs for C.albicans LAM-1 were typical of those for other C.albicans isolates (flucytosine, 0.125 μg/ml; amphotericin B, 1 μg/ml; fluconazole, 0.25 μg/ml; itraconazole, 0.125 μg/ml; posaconazole, 0.031 μg/ml; voriconazole, 0.031 μg/ml; caspofungin, 1 μg/ml; micafungin [FK-463], 0.031 μg/ml; and anidulafungin [LY-303366], 0.031 μg/ml). This strain was thus susceptible to all classes of antifungal agents tested, including the echinocandins. The MFC for caspofungin (1 μg/ml) was equivalent to the MIC, demonstrating fungicidal activity against C. albicans and in agreement with reported in vitro susceptibility data of C. albicans to this antifungal (6, 8, 15, 28, 33, 45).

When caspofungin was added at concentrations (0.125 to 1 μg/ml) at or below the MIC to late-log-phase C. albicans grown in SDB for 15 h (Fig. 1A), the apparent rate of reduction of the number of CFU per milliliter was unexpectedly inversely proportional to the drug concentration. This effect was correlated with increasing macroscopic and microscopic clumping of C. albicans cells as the concentration of caspofungin decreased. Interestingly, aggregates of C. albicans blastoconidia have been previously observed in an enriched synthetic liquid medium after 4 h of treatment with caspofungin, L-733,560, as well as acidic terpenoid (1, 3)-β-d-glucan synthase inhibitors, at concentrations at or below the MIC or MFC (37; M. Kurtz, personal communication). In another report, however, caspofungin concentrations below that required to inhibit 80% of the strains resulted in growth curves similar to that for the control in the absence of caspofungin for all C. albicans isolates tested and no report of aggregation (14).

FIG. 1.
  • Open in new tab
  • Download powerpoint
FIG. 1.

Plots of the number of C. albicans treated with different concentrations of caspofungin over time. The mean values for log10 of the number of CFU per milliliter versus time for C. albicans strain LAM-1 tested against different concentrations of caspofungin. The following concentrations (in micrograms per milliliter) of caspofungin were used: 0 (control) (□), 0.0625 (▾), 0.125 (♦), 0.25 (•), 1 (▴), 4 (○), 8 (▵), and 16 (▪). Caspofungin was added to cultures in SDB after 15 h of incubation (A) or at the start of culture (B). Representative results are shown from four (A) and two (B) independent experiments.

The apparent enhanced killing of C. albicans at caspofungin concentrations below the MIC may have resulted from the formation of increasingly large aggregates, each giving rise to a single colony and consequently being counted as 1 CFU. Aggregation was not prevented by adding 0.01% (wt/vol) Tween 20 or 0.0025% Tween 80 (Fisher Scientific, Fair Lawn, N.J.) to the SDB culture medium (data not shown). In addition, time-kill curves constructed by a proposed standardized method (27) in RPM1 1640 buffered with MOPS also resulted in aggregation at values at or below the MIC and in a rate of killing comparable to that in SDB at concentrations (4 to 16 μg/ml) above the MIC or MFC (data not shown). As expected, these higher concentrations of caspofungin (4 to 16 μg/ml) all produced approximately 90% killing of C. albicans within 7 h in SDB medium (Fig. 1A) (8, 14) with no visible aggregation but abundant cellular debris microscopically (14). The absence of additional killing effect against C. albicans at increasing concentrations of caspofungin (4 to 16 μg/ml) has been observed by other investigators (14). Taken together, the results of the time-kill studies suggest that inhibition of synthesis of cell wall glucan by caspofungin primarily alters the surface properties of C. albicans at concentrations below the MIC, causing the cells to aggregate, while killing at concentrations above the MIC or MFC disrupts the cells and aggregation is thus not observed. Interestingly, caspofungin at concentrations below the MIC induces a high-affinity fibronectin receptor that may promote the adhesive properties of C. albicans (M. L. Pendrak, T. J. Walsh, and D. D. Roberts, Prog. Abstr. 6th ASM Conference on Candida and Candidiasis, abstr. 124, 2002).

Time-kill curves were also constructed by adding caspofungin to a smaller inoculum of C. albicans (103 CFU) at the start of culture in SDB and quantitating CFU at determined time points over 20 h of incubation. The apparent reduction in CFU was again inversely proportional to the concentration of caspofungin because of aggregation, but at least 99% killing was achieved within 9 h at higher concentrations (Fig. 1B). However, a persistent fraction of C. albicans was not killed, and growth of the fungus quickly resumed until the end of incubation. It is hypothesized that this rebound in CFU may be the result of decreased drug stability under the extended study conditions (14). Monitoring of the pH at each time point revealed pH values of 5 to 5.5, making it unlikely that caspofungin was inactivated by deviating from the recommended pH range of 5 to 7 (Merck Research Laboratories).

Expression of the SAP1 to SAP9 and PLB1 genes of C. albicans was determined by RT-PCR after the addition of caspofungin (4 to 16 μg/ml) to cells grown for 15 h in SDB. In comparison to a control culture without caspofungin, expression of SAP1 to SAP3, SAP7 to SAP9, PLB1, and the EFB1 positive-control gene was unaltered at these drug concentrations over a period of 7 h (Fig. 2). Interestingly, however, expression of SAP5 increased steadily beginning 1 h after exposure to these concentrations of caspofungin (Fig. 2). Although SAP5 is expressed in vitro by the hyphal form of C. albicans at neutral pH (24, 48), expression has been found using in vivo expression technology in a murine model of esophageal candidiasis when only blastoconidia are observed (42). Although regulation of expression of the SAP genes has not been completely elucidated at the molecular level, it could be hypothesized that induction of expression of SAP5 may have resulted from signaling events occurring in response to cell wall damage by caspofungin. The C. albicans transcriptional regulators CPH1 and EFG1 mediate the activation of the SAP5 gene (43) and may have been up-regulated after exposure to caspofungin. Alternatively, peptide hydrolysis products of the cyclic hexapeptide caspofungin (4) may have induced expression of SAP5, because peptides up-regulate expression of the SAP genes in vitro (24). Because the RT-PCR analysis was conducted on the portion of C. albicans cells exposed to but not yet killed by the antifungal agent, inhibition of 1,3-β-d-glucan synthesis by caspofungin was rapidly fungicidal against C. albicans before the expression of virulence genes could be perturbed. The absence of suppression of expression of SAP genes, PLB1, and the control EFB1 gene by caspofungin concurs with the highly specific inhibition of glucan synthase by the close analogue L-733,560, which begins to show nonspecific effects at 25× MIC (29, 37). In conclusion, it is unlikely that suppression of SAP and PLB1 gene expression by caspofungin occurs at the caspofungin concentrations in plasma found in clinical treatment of candidiasis (10), and such an indirect mechanism would not be expected to contribute to clearance of C. albicans during treatment with caspofungin.

FIG. 2.
  • Open in new tab
  • Download powerpoint
FIG. 2.

Expression of the SAP2, SAP5, and EFB1 genes of C. albicans over a period of 7 h after the addition of caspofungin (4 to 16 μg/ml) to cells grown for 15 h in SDB. Representative results are shown from two independent experiments. EFB1 was used as a positive control. Expression of the remaining SAP genes and PLB1 was similar to that of SAP2.

ACKNOWLEDGMENTS

This study was supported in part by grants from Merck Frosst Canada & Co. and the Canadian Institutes of Health Research/Rx & D Research Program.

We thank Claire St-Onge for preparation of the manuscript.

FOOTNOTES

    • Received 15 March 2002.
    • Returned for modification 27 March 2002.
    • Accepted 11 June 2002.
  • Copyright © 2002 American Society for Microbiology

REFERENCES

  1. 1.↵
    Abruzzo, G. K., A. M. Flattery, C. J. Gill, L. Kong, J. G. Smith, V. B. Pikounis, J. M. Balkovec, A. F. Bouffard, J. F. Dropinski, H. Rosen, H. Kropp, and K. Bartizal. 1997. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother.41:2333-2338.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Abruzzo, G. K., C. J. Gill, A. M. Flattery, L. Kong, C. Leighton, J. G. Smith, V. P. Pikounis, K. Bartizal, and H. Rosen. 2000. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob. Agents Chemother.44:2310-2318.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Angiolella, L., M. Facchin, A. Stringaro, B. Maras, N. Simonetti, and A. Cassone. 1996. Identification of a glucan-associated enolase as a main cell wall protein of Candida albicans and an indirect target of lipopeptide antimycotics. J. Infect. Dis.173:684-690.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    Balani, S. K., X. Xu, B. H. Arison, M. V. Silva, A. Gries, F. A. DeLuna, D. Cui, P. H. Kari, T. Ly, C. E. Hop, R. Singh, M. A. Wallace, D. C. Dean, J. H. Lin, P. G. Pearson, and T. A. Baillie. 2000. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab. Dispos.28:1274-1278.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    Balkovec, J. M., R. M. Black, G. K. Abruzzo, K. Bartizal, S. Dreikorn, and K. Nollstadt. 1993. Pneumocandin antifungal lipopeptides. The phenolic hydroxyl is required for 1,3-β-d-glucan synthesis inhibition. Bioorg. Med. Chem. Lett.3:2039-2042.
    OpenUrlCrossRef
  6. 6.↵
    Barchiesi, F., A. M. Schimizzi, A. W. Fothergill, G. Scalise, and M. G. Rinaldi. 1999. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur. J. Clin. Microbiol. Infect. Dis.18:302-304.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    Barry, A. L., M. A. Pfaller, S. D. Brown, A. Espinel-Ingroff, M. A. Ghannoum, C. Knapp, R. P. Rennie, J. H. Rex, and M. G. Rinaldi. 2000. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J. Clin. Microbiol.38:3457-3459.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    Bartizal, K., C. J. Gill, G. K. Abruzzo, A. M. Flattery, L. Kong, P. M. Scott, J. G. Smith, C. E. Leighton, A. Bouffard, J. F. Dropinski, and J. Balkovec. 1997. In vitro preclinical evaluation studies with the echinocandin antifungal agent MK-0991 (L-743,872). Antimicrob. Agents Chemother.41:2326-2332.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    Bills, G. F., G. Platas, F. Palaez, and P. Mazurekar. 1998. Reclassification of a pneumocandin-producing anamorph, Glarea lozoyensis, gen. et sp. nov., previously identified as Zalerion arboricola. Mycol. Res.103:179-192.
    OpenUrl
  10. 10.↵
    Chavez-Eng, C. M., M. Schwatz, M. L. Constanzer, and B. K. Matuszewski. 1999. Determination of a cyclic hexapeptide, a novel antifungal agent, in human plasma by high-performance liquid chromatography with ion spray and turbo ion spray tandem mass spectrometric detection. J. Chromatogr. B721:229-238.
    OpenUrlCrossRef
  11. 11.↵
    Colina, A. R., F. Aumont, N. Deslauriers, P. Belhumeur, and L. de Repentigny. 1996. Evidence for degradation of gastrointestinal mucin by Candida albicans secretory aspartyl proteinase. Infect. Immun.64:4514-4519.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    Debono, M., and R. S. Gordee. 1994. Antibiotics that inhibit fungal cell wall development. Annu. Rev. Microbiol.48:471-497.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    Dubois, N., A. R. Colina, F. Aumont, P. Belhumeur, and L. de Repentigny. 1998. Overexpression of Candida albicans secretory aspartyl proteinase 2 and its expression in Saccharomyces cerevisiae do not augment virulence in mice. Microbiology144:2299-2310.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    Ernst, E. J., M. E. Klepser, M. E. Ernst, S. A. Messer, and M. A. Pfaller. 1999. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn. Microbiol. Infect. Dis.33:75-80.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    Espinel-Ingroff, A. 1998. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandin MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol.36:2950-2956.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    Espinel-Ingroff, A., C. W. Kish, T. M. Kerkering, R. A. Fromtling, K. Bartizal, J. N. Galgiani, K. Villareal, M. A. Pfaller, T. Gerarden, M. G. Rinaldi, and A. Fothergill. 1992. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J. Clin. Microbiol.30:3138-3145.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    Georgopapadakou, N. H. 2001. Update on antifungals targeted to the cell wall: focus on β-1,3-glucan synthase inhibitors. Exp. Opin. Investig. Drugs10:269-280.
    OpenUrl
  18. 18.↵
    Georgopapadakou, N. H., and T. J. Walsh. 1996. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob. Agents Chemother.40:279-291.
    OpenUrlFREE Full Text
  19. 19.↵
    Ghannoum, M. A. 2000. Potential role of phospholipases in virulence and fungal pathogenesis. Clin. Microbiol. Rev.13:122-143.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    Graybill, J. R., L. K. Najvar, M. F. Luther, and A. W. Fothergill. 1997. Treatment of murine disseminated candidiasis with L-743,872. Antimicrob. Agents Chemother.41:1775-1777.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    Graybill, J. R., R. Bocanegra, M. Luther, A. Fothergill, and M. J. Rinaldi. 1997. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob. Agents Chemother.41:1937-1939.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    Groll, A. H., and T. J. Walsh. 1997. Potential new antifungal agents. Curr. Opin. Infect. Dis.10:449-458.
    OpenUrlCrossRef
  23. 23.↵
    Hube, B. 1996. Candida albicans secreted aspartyl proteinases. Curr. Top. Med. Mycol.7:55-69.
    OpenUrlPubMed
  24. 24.↵
    Hube, B., M. Monod, D. A. Schofield, A. J. Brown, and N. A. R. Gow. 1994. Expression of seven members of the gene family encoding secretory aspartyl proteinases in Candida albicans. Mol. Microbiol.14:87-99.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    Ibrahim, A. S., F. Mirbod, S. G. Filler, Y. Banno, G. T. Cole, Y. Kitajima, J. E. Edwards, Y. Nozawa, and M. A. Ghannoum. 1995. Evidence implicating phospholipase as a virulence factor of Candida albicans. Infect. Immun.63:1993-1998.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    Keating, G. M., and B. Jarvis. 2001. Caspofungin. Drugs61:1121-1129.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    Klepser, M. E., E. J. Ernst, R. E. Lewis, M. E. Ernst, and M. A. Pfaller. 1998. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob. Agents Chemother.42:1207-1212.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    Krishnarao, T. V., and J. N. Galgiani. 1997. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother.41:1957-1960.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    Kurtz, M. B., C. Douglas, J. Marrinan, K. Nollstadt, J. Onishi, S. Dreikorn, J. Milligan, S. Mandala, J. Thompson, J. M. Balkovec, F. A. Bouffard, J. F. Dropinski, M. L. Hammond, R. A. Zambias, G. Abruzzo, K. Bartizal, O. B. McManus, and M. L. Garcia. 1994. Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis. Antimicrob. Agents Chemother.38:2750-2757.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    Kurtz, M. B., I. B. Heath, J. Marrinan, S. Dreikorn, J. Onishi, and C. Douglas. 1994. Morphological effects of pneumocandins against Aspergillus fumigatus correlate with activity against (1,3)-β-d-glucan synthase. Antimicrob. Agents Chemother.38:1480-1489.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    Lacasse, M., C. Fortier, L. Trudel, A. J. Collet, and N. Deslauriers. 1990. Experimental oral candidosis in the mouse: microbiologic and histologic aspects. J. Oral Pathol. Med.19:136-141.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    Leidich, S. D., A. S. Ibrahim, Y. Fu, A. Koul, C. Jessup, J. Vitullo, W. Fonzi, F. Mirbod, S. Nakashima, Y. Nozawa, and M. A. Ghannoum. 1998. Cloning and disruption of caPLB1, a phospholipase B gene involved in the pathogenicity of Candida albicans.J. Biol. Chem.273:26078-26086.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    Marco, F., M. A. Pfaller, S. A. Messer, and R. N. Jones. 1998. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against bloodstream isolates of Candida spp. Diagn. Microbiol. Infect. Dis.31:33-37.
    OpenUrl
  34. 34.↵
    Monod, M., B. Hube, D. Hess, and D. Sanglard. 1998. Differential regulation of SAP8 and SAP9, which encode two new members of the secreted aspartic proteinase family in Candida albicans. Microbiology144:2731-2737.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    Naglik, J. R., G. Newport, T. C. White, L. L. Fernandes-Naglik, J. S. Greenspan, D. Greenspan, S. P. Sweet, S. J. Challacombe, and N. Agabian. 1999. In vivo analysis of secreted aspartyl proteinase expression in human oral candidiasis. Infect. Immun.67:2482-2490.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
  37. 37.↵
    Onishi, J., M. Meinz, J. Thompson, J. Curotto, S. Dreikorn, M. Rosenbach, C. Douglas, G. Abruzzo, A. Flattery, L. Kong, A. Cabello, F. Vicente, F. Pelaez, M. T. Diez, I. Martin, G. Bills, R. Giacobbe, A. Dombrowski, R. Schwartz, S. Morris, G. Harris, A. Tsipouras, K. Wilson, and M. B. Kurtz. 2000. Discovery of novel antifungal (1,3)-β-d-glucan synthase inhibitors. Antimicrob. Agents Chemother.44:368-377.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    Perfect, J. R. 1996. Fungal virulence genes as targets for antifungal chemotherapy. Antimicrob. Agents Chemother.40:1577-1583.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    Pfaller, M. A., F. Marco, S. A. Messer, and R. N. Jones. 1998. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus,Fusarium,Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis.30:251-255.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    Pfaller, M. A., M. Bale, B. Buschelman, M. Lancaster, A. Espinel-Ingroff, J. H. Rex, and M. G. Rinaldi. 1994. Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods. J. Clin. Microbiol.32:1650-1653.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    Ripeau, J. S., M. Fiorillo, F. Aumont, P. Belhumeur, and L. de Repentigny. 2002. Evidence for differential expression of Candida albicans virulence genes during oral infection in intact and human immunodeficiency virus type 1 transgenic mice. J. Infect. Dis.185:1094-1102.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    Staib, P., M. Kretschmar, T. Nichterlein, H. Hof, and J. Morschhauser. 2000. Differential activation of a Candida albicans virulence gene family during infection. Proc. Natl. Acad. Sci. USA97:6102-6107.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    Staib, P., M. Kretschmar, T. Nichterlein, H. Hof, and J. Morschhauser. 2002. Transcriptional regulators Cph1p and Efg1p mediate activation of the Candida albicans virulence gene SAP5 during infection. Infect. Immun.70:921-927.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    Sugiyama, Y., S. Nakashima, F. Mirbod, H. Kanoh, Y. Kitajima, M. A. Ghannoum, and Y. Nozawa. 1999. Molecular cloning of a second phospholipase B gene, caPLB2 from Candida albicans. Med. Mycol.37:61-67.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    Vazquez, J. A., M. Lynch, D. Boikov, and J. D. Sobel. 1997. In vitro activity of a new pneumocandin antifungal agent, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother.41:1612-1614.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    Villanueva, A., E. G. Arathoon, E. Gotuzzo, R. S. Berman, M. J. DiNubile, and C. A. Sable. 2001. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis.33:1529-1535.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    Wanger, A., K. Mills, P. W. Nelson, and J. H. Rex. 1995. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob. Agents Chemother.39:2520-2522.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    White, T. C., and N. Agabian. 1995. Candida albicans secreted aspartyl proteinases: isoenzyme pattern is determined by cell type, and levels are determined by environmental factors. J. Bacteriol.177:5215-5221.
    OpenUrlAbstract/FREE Full Text
  49. 49.↵
    Wu, T., K. Wright, S. F. Hurst, and C. J. Morrison. 2000. Enhanced extracellular production of aspartyl proteinase, a virulence factor, by Candida albicans isolates following growth in subinhibitory concentrations of fluconazole. Antimicrob. Agents Chemother.39:1200-1208.
    OpenUrl
PreviousNext
Back to top
Download PDF
Citation Tools
Effect of the Echinocandin Caspofungin on Expression of Candida albicans Secretory Aspartyl Proteinases and Phospholipase In Vitro
Jean-Sébastien Ripeau, Francine Aumont, Pierre Belhumeur, Luis Ostrosky-Zeichner, John H. Rex, Louis de Repentigny
Antimicrobial Agents and Chemotherapy Sep 2002, 46 (9) 3096-3100; DOI: 10.1128/AAC.46.9.3096-3100.2002

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Effect of the Echinocandin Caspofungin on Expression of Candida albicans Secretory Aspartyl Proteinases and Phospholipase In Vitro
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Effect of the Echinocandin Caspofungin on Expression of Candida albicans Secretory Aspartyl Proteinases and Phospholipase In Vitro
Jean-Sébastien Ripeau, Francine Aumont, Pierre Belhumeur, Luis Ostrosky-Zeichner, John H. Rex, Louis de Repentigny
Antimicrobial Agents and Chemotherapy Sep 2002, 46 (9) 3096-3100; DOI: 10.1128/AAC.46.9.3096-3100.2002
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • Candida strains.
    • Antifungal susceptibility testing.
    • Time-kill curve procedures.
    • RT-PCR.
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
antifungal agents
Aspartic Acid Endopeptidases
Candida albicans
Gene Expression Regulation, Enzymologic
peptides
Peptides, Cyclic
Phospholipases

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596